

23 October 2025

New Patients in Gastroenterology

How many new patients were treated by the Trust's Gastroenterology Department in the latest 3 month period of July, August and September (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Crohn's disease and Ulcerative colitis? I have provided a table below. Some treatments can only be used for one condition, which I have blocked out.

Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time? If a patient received any of the below treatments before the 1st July 2025, they are not classed as a new patient for the purposes of this question.

| | Total Gastroenterology Department | Crohn's Disease | Ulcerative Colitis |
|------------------------------|-----------------------------------|-----------------|--------------------|
| Adalimumab [Humira] | nil | | |
| Adalimumab [All Biosimilar] | 19 | 18 | 1 |
| Etrasimod | nil | | |
| Filgotinib | 4 | | 4 |
| Golimumab | nil | | |
| Infliximab [Remicade] | nil | | |
| Infliximab [All Biosimilar] | 14 | 12 | 2 |
| Mirikizumab | 9 | 6 | 3 |
| Ozanimod | nil | | |
| Risankizumab | 11 | 11 | |
| Tofacitinib | nil | | |
| Upadacitinib | 11 | 5 | 6 |
| Ustekinumab [Stelara] | nil | | |
| Ustekinumab [All Biosimilar] | 44 | 31 | 13 |
| Vedolizumab | 11 | 2 | 9 |